EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

Trial Profile

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Pemetrexed (Primary) ; Cisplatin; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms effect
  • Most Recent Events

    • 20 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top